Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.
Dow Chemical (DOW): In an exclusive interview, Cramer spoke with Andrew Liveris, Dow's CEO, for an update on the company's transformation from a commodity to specialty chemical company.
Liveris said that for Dow, productivity is "a journey, not a destination," which is why his company is continually adopting a "less is more" strategy and becoming more technology driven and focused on customers. Dow has a portfolio of products that works no matter what the price of oil, Liveris continued, something that had not historically been the case.
When asked about Europe, Liveris said the demand is there in countries like Germany and with a strong dollar, Europe's economy is finally starting to move.
Turning to the topic of chlorine, a business Dow is in the process of spinning off, Liveris said Dow started in the chlorine business but now realizes that its capital can be better invested in higher-growth areas.
Isis Pharmaceuticals (ISIS): Cramer sat down with Dr. Stanley Crooke, chairman and CEO of Isis, a stock that's up over 350% since Cramer first got behind the company in October 2012. Isis currently has 38 different drugs under development.
Crooke commented on today's news that Isis has entered into a licensing deal with Bayer (BAYRY) for its expected blockbuster blood-thinning drug, currently named Factor 11, or FRXI. He said Isis explored many possible partners, but Bayer knows the space and has the experience and commitment to make FRXI the huge success they know it will be.
Crooke said that Isis will explain the deal in a lot more detail on Tuesday's earnings call.
Additionally, Crooke said that Isis will be providing updates soon on its muscular dystrophy and diabetes trials and will have more news regarding Akcea Therapeutics, its new subsidiary dedicated to the development of the next generation of lipid drugs.
Among the four, Cramer felt only Wells Fargo, an Action Alerts PLUS name, was worth owning. He said that American Express has lost its edge to the faster-growing Visa (V) and MasterCard (MA), and losing its partnership with Costco (COST) was a big loss.
Cramer felt that Coca-Cola was intriguing, not for its business but for its investments in Keurig Green Mountain (GMCR) and Monster Beverage (MNST). That said, investors would be better served owning Pepsico (PEP).
IBM is a work in progress, but does offer a dividend while the company reinvents itself once again.
Then there's Wells Fargo, a bank that's only one interest rate hike away from sizable gains as the American economy continues to strengthen.
To read a full recap of "Mad Money" on CNBC, click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.